Ashland expands pharmaceutical plant for Aquarius™ tablet coatings and commissions new microbial protection capability in Brazil, demonstrating strategy to globalize, innovate, and invest
Ashland has completed a $10 million expansion of its pharmaceutical manufacturing plant in Cabreúva, Brazil, with a ribbon-cutting ceremony scheduled for April 4, 2025. The investment aims to meet growing market demand for coated tablets in Latin America, where consumption grew 4.3% annually between 2019-2023, with Brazil reaching 5.7% yearly growth.
The expansion includes modernization of microbial protection equipment at the R&D laboratory in São Paulo, following previous investments in Ireland and China. The new state-of-the-art facilities enhance Ashland's capabilities in tablet coatings application, color matching, stability, and quality evaluation. Local employees received specialized training at US headquarters to ensure optimal performance.
In 2023, Ashland introduced seven new platform technologies focused on sustainable innovations in personal care, pharmaceuticals, and coatings sectors. The company has already launched several patented innovations from their Transformed Vegetable Oils and Super Wetters platforms.
Ashland ha completato un'espansione da 10 milioni di dollari del suo stabilimento di produzione farmaceutica a Cabreúva, in Brasile, con una cerimonia di inaugurazione prevista per il 4 aprile 2025. L'investimento mira a soddisfare la crescente domanda di mercato per le compresse rivestite in America Latina, dove il consumo è cresciuto del 4,3% all'anno tra il 2019 e il 2023, con il Brasile che ha raggiunto una crescita annuale del 5,7%.
L'espansione include la modernizzazione delle attrezzature di protezione microbica presso il laboratorio di R&D a São Paulo, a seguito di precedenti investimenti in Irlanda e Cina. Le nuove strutture all'avanguardia migliorano le capacità di Ashland nell'applicazione di rivestimenti per compresse, abbinamento dei colori, stabilità e valutazione della qualità. I dipendenti locali hanno ricevuto formazione specializzata presso la sede centrale negli Stati Uniti per garantire prestazioni ottimali.
Nel 2023, Ashland ha introdotto sette nuove tecnologie di piattaforma focalizzate su innovazioni sostenibili nei settori della cura personale, farmaceutico e rivestimenti. L'azienda ha già lanciato diverse innovazioni brevettate dalle loro piattaforme di Oli Vegetali Trasformati e Super Wetters.
Ashland ha completado una expansión de 10 millones de dólares en su planta de fabricación farmacéutica en Cabreúva, Brasil, con una ceremonia de corte de cinta programada para el 4 de abril de 2025. La inversión tiene como objetivo satisfacer la creciente demanda del mercado de tabletas recubiertas en América Latina, donde el consumo creció un 4.3% anualmente entre 2019 y 2023, alcanzando Brasil un crecimiento del 5.7% anual.
La expansión incluye la modernización del equipo de protección microbiana en el laboratorio de I+D en São Paulo, siguiendo inversiones previas en Irlanda y China. Las nuevas instalaciones de última generación mejoran las capacidades de Ashland en la aplicación de recubrimientos para tabletas, coincidencia de colores, estabilidad y evaluación de calidad. Los empleados locales recibieron capacitación especializada en la sede central de EE. UU. para garantizar un rendimiento óptimo.
En 2023, Ashland presentó siete nuevas tecnologías de plataforma centradas en innovaciones sostenibles en los sectores de cuidado personal, farmacéuticos y recubrimientos. La empresa ya ha lanzado varias innovaciones patentadas de sus plataformas de Aceites Vegetales Transformados y Super Wetters.
Ashland는 브라질 카브레바에 있는 제약 제조 공장을 1억 달러 규모로 확장 완료했으며, 2025년 4월 4일에 리본 커팅 행사도 예정되어 있습니다. 이번 투자는 2019년부터 2023년까지 연평균 4.3% 증가한 라틴 아메리카의 코팅 정제에 대한 증가하는 시장 수요를 충족하기 위한 것입니다. 브라질은 연간 5.7%의 성장을 기록했습니다.
이번 확장에는 이전에 아일랜드와 중국에 대한 투자에 이어 상파울루의 R&D 실험실에서 미생물 보호 장비의 현대화가 포함됩니다. 새로운 최첨단 시설은 Ashland의 정제 코팅 적용, 색상 일치, 안정성 및 품질 평가 능력을 향상시킵니다. 현지 직원들은 최적의 성능을 보장하기 위해 미국 본사에서 전문 교육을 받았습니다.
2023년, Ashland는 개인 관리, 제약 및 코팅 분야에서 지속 가능한 혁신에 중점을 둔 7개의 새로운 플랫폼 기술을 도입했습니다. 이 회사는 이미 변형 식물성 기름 및 슈퍼 웨터 플랫폼에서 여러 가지 특허 받은 혁신을 출시했습니다.
Ashland a achevé une expansion de 10 millions de dollars de son usine de fabrication pharmaceutique à Cabreúva, au Brésil, avec une cérémonie d'inauguration prévue pour le 4 avril 2025. Cet investissement vise à répondre à la demande croissante du marché pour les comprimés enrobés en Amérique latine, où la consommation a augmenté de 4,3 % par an entre 2019 et 2023, le Brésil atteignant une croissance annuelle de 5,7 %.
L'expansion comprend la modernisation des équipements de protection microbienne au laboratoire de R&D à São Paulo, suite à des investissements antérieurs en Irlande et en Chine. Les nouvelles installations à la pointe de la technologie améliorent les capacités de Ashland en matière d'application de revêtements de comprimés, d'appariement des couleurs, de stabilité et d'évaluation de la qualité. Les employés locaux ont reçu une formation spécialisée au siège américain pour garantir des performances optimales.
En 2023, Ashland a introduit sept nouvelles technologies de plateforme axées sur des innovations durables dans les secteurs des soins personnels, de la pharmacie et des revêtements. L'entreprise a déjà lancé plusieurs innovations brevetées de ses plateformes d'Huiles Végétales Transformées et de Super Wetters.
Ashland hat eine Erweiterung seiner pharmazeutischen Produktionsstätte in Cabreúva, Brasilien, im Wert von 10 Millionen Dollar abgeschlossen, mit einer Eröffnungszeremonie, die für den 4. April 2025 geplant ist. Die Investition zielt darauf ab, die wachsende Marktnachfrage nach beschichteten Tabletten in Lateinamerika zu decken, wo der Verbrauch zwischen 2019 und 2023 jährlich um 4,3 % gestiegen ist, wobei Brasilien ein jährliches Wachstum von 5,7 % erreicht hat.
Die Erweiterung umfasst die Modernisierung der mikrobiologischen Schutzgeräte im F&E-Labor in São Paulo, nach früheren Investitionen in Irland und China. Die neuen hochmodernen Einrichtungen verbessern die Fähigkeiten von Ashland in der Anwendung von Tablettenbeschichtungen, Farbangleichung, Stabilität und Qualitätsbewertung. Lokale Mitarbeiter erhielten eine spezialisierte Schulung in der US-Zentrale, um eine optimale Leistung sicherzustellen.
Im Jahr 2023 führte Ashland sieben neue Plattformtechnologien ein, die sich auf nachhaltige Innovationen in den Bereichen Körperpflege, Pharmazie und Beschichtungen konzentrieren. Das Unternehmen hat bereits mehrere patentierte Innovationen aus seinen Plattformen für transformierte Pflanzenöle und Super Wetters auf den Markt gebracht.
- Strategic $10M investment expanding pharmaceutical manufacturing capacity in high-growth market
- Strong market growth metrics: Brazil 5.7% annual growth, Latin America 4.3%
- Enhanced R&D capabilities with new state-of-the-art equipment
- Launch of seven new platform technologies with patented innovations
- None.
Insights
Ashland's
This expansion follows Ashland's strategic investments in Ireland and China, creating a more robust global manufacturing network that provides three key advantages: regionalized production to reduce supply chain costs, technical support proximity to customers, and R&D capabilities to develop customized solutions. The focus on coatings and microbial protection demonstrates Ashland's continued shift toward higher-margin specialty chemicals rather than commodity products.
While modest relative to Ashland's
This capital deployment shows disciplined execution of the company's platform strategy launched in 2023, which prioritizes technical differentiation through specialty innovations rather than bulk chemical production. For investors, this represents continued progress in Ashland's transformation toward higher-margin, less cyclical specialty businesses with stronger barriers to entry.
Increased production capacity and market presence expected to drive competitive position and organic growth; follows previous investments in Ireland and China
Wilmington, Del., April 01, 2025 (GLOBE NEWSWIRE) -- Ashland has completed a 10-million-dollar expansion of its pharmaceutical manufacturing plant in Cabreúva, Brazil and will celebrate the occasion with a ribbon-cutting ceremony on April 4, 2025.
The investment significantly expands Ashland’s pharmaceutical footprint in the region and capabilities to meet increasing market demand for coated tablets in Latin America and Brazil. Between 2019 and 2023 the consumption of coated tablets in Latin America had an average growth of 4.3 percent per year, while Brazil has reached growth of 5.7 percent per year+.
The investment also includes the modernization of equipment for microbial protection in personal care applications at the Research and Development (R&D) laboratory of the company's Technical Center in São Paulo and follows the company’s previous investments to expand their bioresorbable polymers facility in Mullingar, Ireland and biofunctionals R&D lab in Shanghai, China.
“Our focused actions continue to demonstrate Ashland’s strategies to globalize, innovate and invest as a means of driving superior differentiation for customers and increase shareholder value,” said Guillermo Novo, chair and chief executive officer, Ashland. “The investments we have made in Cabreúva and São Paulo are supporting the globalization of our expertise in tablet coatings and microbial protection. They ensure even more innovation, collaboration and technical support for Ashland customers.”
The new state-of-the-art equipment enhances Ashland’s capabilities in tablet coatings application, color matching, stability and quality evaluation. Through enhancements to the R&D lab, Ashland can offer customized solutions to industry needs, and innovative solutions with ultra-high solids coatings, moisture protection, odor and flavor masking, and modified release systems. To ensure optimal performance, local Ashland employees underwent specialized training at the company’s headquarters in the United States and with equipment manufacturers.
“Our investments are focused on meeting growing market demand in Brazil and Latin America with more efficiency and technology,” said Alessandra Faccin, senior vice president and general manager, life sciences, Ashland. “The new plant accommodates high-performance production, and offers our customers differentiated technical support from formulation design to industrial scale, enabling new innovations and organic growth."
“In personal care, we are excited to commission the local production of microbial protection products in Brazil,” said Hamilton Oliveira Junior, general manager, Latin America, personal care, Ashland. “This investment is a key part of our globalization strategy and will serve as a source of differentiation as we innovate and position supply closer to our customers.”
"We believe this is the ideal time to expand our operations and strengthen our presence in the region,” said Brenda Rangel, regional leader, Latin America, Ashland. “The pharmaceutical and personal care industries are in full evolution, and Ashland will continue being a strategic innovation partner for the industry, offering high-performance products and services."
To further institute organic growth for Ashland as well as customers, in 2023, Ashland introduced seven new platform technologies aligned to the company’s core that extend to secondary markets with new and differentiated capabilities. Ashland’s platform solutions bring “new to the world,” sustainable innovations, offering choice to customers and consumers in personal care, pharmaceuticals, coatings and more, enabling customers to reshape global megatrends and respond to various regulatory landscapes worldwide. Ashland has introduced several patented innovations derived from the Transformed Vegetable Oils and Super Wetters platforms with more expected this year under additional platform technologies.
To learn more, visit:
www.ashland.com/cab-platforms
www.ashland.com/cab-randdpg
About Ashland
Ashland Inc. (NYSE: ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for environmental, social, and governance (ESG). The company serves customers in a wide range of consumer and industrial markets, including architectural coatings, construction, energy, food and beverage, nutraceuticals, personal care, and pharmaceutical. Approximately 3,200 passionate, tenacious solvers – from renowned scientists and research chemists to talented engineers and plant operators – thrive on developing practical, innovative, and elegant solutions to complex problems for customers in more than 100 countries. Visit ashland.com and ashland.com/ESG to learn more.
+. data from IQVIA
™ Trademark, Ashland, or its subsidiaries, registered in various countries.
| Investor Relations Ashland: | Media Relations Ashland: |
| William C. Whitaker | Carolmarie C. Brown |
| +1 (614) 790-2095 | +1 (302) 995-3158 |
| wcwhitaker@ashland.com | ccbrown@ashland.com |
| Media Relations Ashland Brazil: |
| Cristina Friedman |
| +55 11 98318-2529 |
| herrero.cristina@gmail.com |
Attachment
FAQ
What is the value and purpose of Ashland's (ASH) Brazil plant expansion?
What is the tablet coating market growth rate in Brazil where ASH is expanding?
How many new platform technologies did Ashland (ASH) introduce in 2023?
What capabilities are enhanced by ASH's new Brazil facility expansion?
